Samuel Lee

Samuel Lee, MD, MBA, is a distinguished co-founder, president, and chief business officer of Eikonoklastes Therapeutics, Inc., an innovative biopharmaceutical company focused on addressing neurodegenerative diseases. In addition, Samuel serves as an executive in residence and director at CincyTech USA, where efforts are dedicated to transforming innovations into successful life sciences and high-tech enterprises. Samuel's extensive experience includes roles as a principal in life sciences at American Gene Technologies® International Inc. and as an angel investor in multiple companies, including Vincere Biosciences and Swift Solar. Samuel Lee holds a Doctor of Medicine from the University of Cincinnati, an MBA from Stanford University Graduate School of Business, and a Master’s in Public Health from The Johns Hopkins University.